- Home
- NTLA vs FWRG Comparison
NTLA vs FWRG Comparison
Compare NTLA & FWRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- FWRG
- Stock Information
- Founded
- NTLA 2014
- FWRG 1983
- Country
- NTLA United States
- FWRG United States
- Employees
- NTLA N/A
- FWRG N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- FWRG Restaurants
- Sector
- NTLA Health Care
- FWRG Consumer Discretionary
- Exchange
- NTLA Nasdaq
- FWRG Nasdaq
- Market Cap
- NTLA 1.0B
- FWRG 1.0B
- IPO Year
- NTLA 2016
- FWRG 2021
- Fundamental
- Price
- NTLA $9.62
- FWRG $17.04
- Analyst Decision
- NTLA Buy
- FWRG Strong Buy
- Analyst Count
- NTLA 18
- FWRG 10
- Target Price
- NTLA $39.44
- FWRG $22.70
- AVG Volume (30 Days)
- NTLA 3.8M
- FWRG 682.5K
- Earning Date
- NTLA 05-08-2025
- FWRG 03-11-2025
- Dividend Yield
- NTLA N/A
- FWRG N/A
- EPS Growth
- NTLA N/A
- FWRG N/A
- EPS
- NTLA N/A
- FWRG 0.30
- Revenue
- NTLA $57,877,000.00
- FWRG $1,015,910,000.00
- Revenue This Year
- NTLA N/A
- FWRG $18.22
- Revenue Next Year
- NTLA N/A
- FWRG $13.49
- P/E Ratio
- NTLA N/A
- FWRG $58.20
- Revenue Growth
- NTLA 59.55
- FWRG 13.95
- 52 Week Low
- NTLA $8.30
- FWRG $12.90
- 52 Week High
- NTLA $28.88
- FWRG $25.98
- Technical
- Relative Strength Index (RSI)
- NTLA 44.22
- FWRG 31.74
- Support Level
- NTLA $8.64
- FWRG $16.33
- Resistance Level
- NTLA $10.68
- FWRG $19.08
- Average True Range (ATR)
- NTLA 0.91
- FWRG 1.14
- MACD
- NTLA -0.09
- FWRG -0.45
- Stochastic Oscillator
- NTLA 30.48
- FWRG 12.54
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.